Last 7 days
0.3%
Last 30 days
-7.8%
Last 90 days
-10.0%
Trailing 12 Months
-1.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 396.9B | 94.9B | -5.16% | -10.64% | 22.12 | 4.18 | 1.25% | -14.07% |
LLY | 298.8B | 28.5B | -5.67% | 20.74% | 47.85 | 10.47 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.2B | 100.3B | -8.43% | -20.95% | 7.21 | 2.25 | 23.43% | 42.74% |
BMY | 142.4B | 46.2B | -7.78% | -1.12% | 22.5 | 3.08 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.5B | 4.5B | -0.20% | -5.41% | -32.05 | 1.01 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.78 | 2.67 | 18.18% | -18.59% |
CGC | 923.6M | 478.9M | -11.35% | -65.42% | -0.29 | 1.93 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 726.9M | 114.5M | -15.28% | -37.42% | -4.31 | 6.35 | 27.90% | 57.40% |
ACRS | 539.5M | 29.8M | -40.95% | -47.43% | -6.21 | 18.13 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -1.2% | 46,159 | 46,738 | 47,144 | 46,960 | 46,385 |
S&GA Expenses | -1.1% | 7,814 | 7,902 | 7,760 | 7,855 | 7,690 |
R&D Expenses | -0.1% | 9,509 | 9,517 | 10,079 | 10,236 | 10,195 |
Costs and Expenses | -1.5% | 38,446 | 39,026 | 39,484 | 39,705 | 38,287 |
EBITDA | -0.3% | 19,389 | 19,446 | 19,546 | 19,355 | - |
EBITDA Margin | 1.0% | 0.42* | 0.42* | 0.42* | 0.41* | - |
Earnings Before Taxes | 0.0% | 7,713 | 7,712 | 7,660 | 7,255 | 8,098 |
EBT Margin | 1.3% | 0.17* | 0.17* | 0.16* | 0.15* | - |
Interest Expenses | -0.9% | 1,400 | 1,413 | 1,442 | 1,500 | - |
Net Income | -5.2% | 6,327 | 6,677 | 6,617 | 6,251 | 6,994 |
Net Income Margin | -4.1% | 0.14* | 0.14* | 0.14* | 0.13* | - |
Free Cahsflow | -6.1% | 11,948 | 12,725 | 14,281 | 15,142 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -1.4% | 96,820 | 98,196 | 100,357 | 103,034 | 109,314 |
Current Assets | 1.8% | 27,273 | 26,796 | 30,186 | 30,121 | 33,262 |
Cash Equivalents | 18.0% | 9,123 | 7,734 | 10,750 | 12,369 | 13,979 |
Inventory | 12.8% | 2,339 | 2,074 | 2,142 | 2,104 | 2,095 |
Net PPE | 3.6% | 6,255 | 6,035 | 5,970 | 6,047 | 6,049 |
Goodwill | 0.2% | 21,149 | 21,112 | 20,446 | 20,500 | 20,502 |
Liabilities | 0.4% | 65,702 | 65,462 | 67,696 | 71,389 | 73,308 |
Current Liabilities | 15.6% | 21,890 | 18,930 | 20,915 | 22,821 | 21,868 |
LT Debt, Current | -59.0% | 1,903 | 4,646 | 7,297 | 4,764 | - |
LT Debt, Non Current | -5.2% | 35,056 | 36,966 | 37,107 | 37,450 | 39,605 |
Shareholder's Equity | -4.9% | 31,061 | 32,671 | 32,600 | 31,580 | 35,946 |
Retained Earnings | 3.4% | 25,503 | 24,675 | 24,217 | 23,948 | 23,820 |
Additional Paid-In Capital | 0.5% | 45,165 | 44,956 | 44,375 | 43,756 | 44,361 |
Shares Outstanding | -0.4% | 2,126 | 2,135 | 2,129 | - | - |
Minority Interest | -9.5% | 57.00 | 63.00 | 61.00 | 65.00 | 60.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -5.4% | 13,066 | 13,817 | 15,396 | 16,195 | 16,207 |
Share Based Compensation | -3.0% | 457 | 471 | 498 | 539 | 583 |
Cashflow From Investing | 43.3% | -1,062 | -1,874 | -769 | -300 | -538 |
Cashflow From Financing | 4.1% | -16,962 | -17,683 | -14,920 | -14,582 | -16,224 |
Dividend Payments | 1.0% | 4,634 | 4,588 | 4,524 | 4,473 | 4,396 |
Buy Backs | -5.3% | 8,001 | 8,452 | 8,276 | 9,512 | 6,287 |
48.1%
1.9%
0%
Y-axis is the maximum loss one would have experienced if Bristol-Myers Squibb was unfortunately bought at previous high price.
8.6%
4.0%
3.2%
10.1%
FIve years rolling returns for Bristol-Myers Squibb.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 5.8 | 1,002,450 | 15,186,500 | 0.42% |
2023-03-13 | Claro Advisors LLC | added | 20.27 | 145,154 | 1,313,150 | 0.43% |
2023-03-10 | MATHER GROUP, LLC. | added | 61.00 | 277,270 | 717,270 | 0.01% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | -47.00 | 32,953 | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -1.68 | -802,303 | 160,959,000 | 0.18% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | added | 0.42 | 71,000 | 4,437,000 | 0.69% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 16.1 | 293,781 | 1,843,780 | 0.15% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -3.37 | -1,172,000 | 52,076,000 | 0.26% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | unchanged | - | 38,515 | 3,195,520 | 1.21% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -8.03 | -56,783 | 769,217 | 0.05% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 9.54% | 202,927,620 | SC 13G/A | |
Feb 07, 2023 | blackrock inc. | 8.1% | 172,720,377 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 9.00% | 199,834,483 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.6% | 169,226,706 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 8.82% | 199,340,458 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 7.6% | 172,464,804 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 8.32% | 194,860,154 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 7.3% | 171,343,446 | SC 13G/A | |
Jan 28, 2020 | wellington management group llp | 3.57% | 83,470,877 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 33.86 -49.44% | 40.90 -38.93% | 62.78 -6.26% | 117.02 74.73% | 143.97 114.98% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-10 | Mily Elizabeth | acquired | - | - | 3,458 | evp, strategy & bd |
2023-03-10 | Powell Ann | sold (taxes) | -1,104,590 | 65.71 | -16,810 | evp, chief human resources |
2023-03-10 | Hirawat Samit | acquired | - | - | 38,978 | evp,chief med.offr.,drug dev. |
2023-03-10 | BOERNER CHRISTOPHER S. | acquired | - | - | 8,568 | evp, chief commercial officer |
2023-03-10 | LEUNG SANDRA | acquired | - | - | 8,731 | evp, general counsel |
2023-03-10 | Mily Elizabeth | sold (taxes) | -922,568 | 65.71 | -14,040 | evp, strategy & bd |
2023-03-10 | Hirawat Samit | sold (taxes) | -1,471,580 | 65.71 | -22,395 | evp,chief med.offr.,drug dev. |
2023-03-10 | Mily Elizabeth | acquired | - | - | 29,636 | evp, strategy & bd |
2023-03-10 | Elkins David V | acquired | - | - | 71,871 | evp, chief financial officer |
2023-03-10 | Caforio Giovanni | acquired | - | - | 234,676 | board chair and ceo |
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) $ in Millions | 12 Months Ended | ||||
---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||
Total Revenues | $ 46,159 | $ 46,385 | $ 42,518 | ||
Cost of products sold | [1] | 10,137 | 9,940 | 11,773 | |
Marketing, selling and administrative | 7,814 | 7,690 | 7,661 | ||
Research and development | 9,509 | 10,195 | 10,048 | ||
Acquired IPRD | 815 | 1,159 | 12,533 | ||
Amortization of acquired intangible assets | 9,595 | 10,023 | 9,688 | ||
Other (income)/expense, net | 576 | (720) | (2,314) | ||
Total Expenses | 38,446 | 38,287 | 49,389 | ||
Earnings/(Loss) Before Income Taxes | 7,713 | 8,098 | (6,871) | ||
Provision for Income Taxes | 1,368 | 1,084 | 2,124 | ||
Net Earnings/(Loss) | 6,345 | 7,014 | (8,995) | ||
Noncontrolling Interest | 18 | 20 | 20 | ||
Net Earnings(Loss) Attributable to BMS | $ 6,327 | $ 6,994 | $ (9,015) | ||
Earnings per common share attributable to BMS, basic (in usd per share) | $ 2.97 | $ 3.15 | $ (3.99) | ||
Earnings per common share attributable to BMS, diluted (in usd per share) | $ 2.95 | $ 3.12 | $ (3.99) | ||
Net product sales | |||||
Total Revenues | $ 44,671 | $ 45,055 | $ 41,321 | ||
Alliance and other revenues | |||||
Total Revenues | $ 1,488 | $ 1,330 | $ 1,197 | ||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 9,123 | $ 13,979 |
Marketable debt securities | 130 | 2,987 |
Receivables | 9,886 | 9,369 |
Inventories | 2,339 | 2,095 |
Other current assets | 5,795 | 4,832 |
Total Current Assets | 27,273 | 33,262 |
Property, plant and equipment | 6,255 | 6,049 |
Goodwill | 21,149 | 20,502 |
Other intangible assets | 35,859 | 42,527 |
Deferred income taxes | 1,344 | 1,439 |
Other non-current assets | 4,940 | 5,535 |
Total Assets | 96,820 | 109,314 |
Current Liabilities: | ||
Short-term debt obligations | 4,264 | 4,948 |
Accounts payable | 3,040 | 2,949 |
Other current liabilities | 14,586 | 13,971 |
Total Current Liabilities | 21,890 | 21,868 |
Deferred income taxes | 2,166 | 4,501 |
Long-term debt | 35,056 | 39,605 |
Other non-current liabilities | 6,590 | 7,334 |
Total Liabilities | 65,702 | 73,308 |
Commitments and contingencies | ||
Bristol-Myers Squibb Company Shareholders’ Equity: | ||
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $50 per share | 0 | 0 |
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021 | 292 | 292 |
Capital in excess of par value of stock | 45,165 | 44,361 |
Accumulated other comprehensive loss | (1,281) | (1,268) |
Retained earnings | 25,503 | 23,820 |
Less cost of treasury stock — 825 million common shares in 2022 and 747 million common shares in 2021 | (38,618) | (31,259) |
Total Bristol-Myers Squibb Company Shareholders’ Equity | 31,061 | 35,946 |
Noncontrolling interest | 57 | 60 |
Total Equity | 31,118 | 36,006 |
Total Liabilities and Equity | $ 96,820 | $ 109,314 |